The FDA granted expedited approval to daraxonrasib, the first pill to directly target common KRAS mutations in pancreatic cancer. A company-funded trial showed median survival of 13.2 months versus 6.7 months for chemotherapy; a one-month supply will cost about $39,800.
Daraxonrasib (brand name Rasonque) received expedited FDA approval to treat advanced metastatic pancreatic cancer by targeting mutated RAS proteins.
A randomized study of 500 patients showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy.
The approval arrived more than six months ahead of the FDA target date and follows expanded access that had already allowed some patients to receive the drug.
Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, which blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.
"This medicine is not a cure but a significant improvement." Pancreatic cancer is among the most deadly forms in large part because it is hard to detect before it starts spreading to other organs. Two juveniles arrested after fight at East Ascension High School The drug garnered public attention earlier this year when former Sen. The daily pills will be sold by Revolution Medicines under the brand name Rasonque.
It's an approach that previously eluded drugmakers for decades. "This is one of the most anticipated approvals I can think of," said Dr. Andrew Coveler of the Fred Hutch Cancer Center.
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer, by blocking a protein that fuels tumor growth in the vast majority of cases.
The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blo
The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blo
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.
Find the latest AMRC news, details about meetings and events, and keep up to date with our newsletters and blogs. News Blog Events Newsletters Networks and groups
Top News Abridge rolls out its context-aware clinical decision support ...
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.